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Lesson of the week
Opiate toxicity in patients with renal failure
B R Conway, D G Fogarty, W E Nelson, C C Doherty
Opiates and their metabolites are known to accumu-
late in renal failure, with increased potential for
toxicity, the most serious aspect of which is respiratory
failure.1 Despite this knowledge, we continue to see life
threatening cases of opiate toxicity in patients with
renal failure, two recent examples of which we present
below.
Case reports
Case 1
A 68 year old woman with type 2 diabetes, angina, and
obesity had an uncomplicated below knee amputation.
Baseline creatinine was 133 mol/l (estimated
glomerular filtration rate 36 ml/min).2 In the first 36
hours after surgery she received 50 mg of morphine
and 76 mg of codeine. On the second day she
developed oliguria despite intravenous fluid resuscita-
tion, and her serum creatinine rose to 213 mol/l. She
became increasingly drowsy and her respiratory rate
fell to 8 breaths/min. Opiate toxicity was suspected
after consultation with the on-call nephrologist. She
did not respond to 400 g intravenous naloxone, how-
ever, and therefore she was transferred to the regional
renal unit.
On admission she was drowsy and uncommunica-
tive. Observations showed oxygen saturation 91% on
28% inspired oxygen; respiratory rate 6 breaths/min;
pulse 50 beats/min, and blood pressure 132/68 mm
Hg. Pupils were pinpoint. Initial investigations detected
sodium 130 mmol/l, potassium 7.6 mmol/l, urea 28.4
mmol/l, creatinine 320 mol/l, pH 7.39, Po2 7.9 kPa,
and Pco2 5.9 kPa. Electrocardiogram showed no
hyperkalaemic changes. We noticed that the cannula
previously used to administer naloxone had tissued.
We gave 400 g of naloxone via a new cannula, and her
Glasgow coma scale score improved to 14/15, and her
respiratory rate rose to 14 breaths/min. We started a
naloxone infusion, which was titrated to maintain her
respiratory rate above 12 breaths/min. Her hyperka-
laemia was managed conservatively. Within hours her
urinary output increased, and in the following days her
serum creatinine returned to baseline.
Case 2
A 63 year old woman with end stage renal failure, type
2 diabetes, and ischaemic heart disease was found
semiconscious in bed. On the way to hospital she
stopped breathing, and on arrival at the emergency
department she was in cardiorespiratory arrest. We
started cardiopulmonary resuscitation, and we intu-
bated and ventilated her. After 90 seconds of pulseless
electrical activity, we obtained cardiac output, and she
became haemodynamically stable. Although she was
obeying commands and resisting the endotracheal
tube, she made no respiratory effort, therefore we
sedated and paralysed her, and transferred her to the
intensive care unit. Investigations found 17.4 mmol/l
blood sugar, pH 7.02, Po2 23.9 kPa, and Pco2 9.5 kPa.
An electrocardiogram showed a junctional rhythm,
rate 50 beats/min, with no ischaemic changes. A chest
radiograph was normal.
In the intensive care unit her pupils were noted to
be small despite previous atropine and adrenaline
administration. It was ascertained that she had been
taking four tablets of Distalgesic (32.5 mg dextropro-
poxyphene hydrochloride and 325 mg paracetamol) a
day for back pain for several days. We haemodialysed
her for three hours, after which we extubated her. She
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subsequently made a full recovery, and we advised her
against taking further opioid analgesics.
Discussion
The altered pharmacokinetics of opiates in renal
failure may result in the accumulation of the parent
compound or an active metabolite. Morphine, for
example, is metabolised to morphine-3-glucuronide
and morphine-6-glucuronide, both of which are
renally excreted. Morphine-6-glucuronide, which is
more potent than morphine itself, has a half life of
about 50 hours in patients with end stage renal failure
compared with 3-5 hours in the presence of normal
renal function.3 Pethidine, another commonly pre-
scribed opiate, is converted to the neurotoxic renally
excreted metabolite norpethidine. Patients with renal
dysfunction are therefore susceptible to opiate toxicity
unless doses are reduced or dosing intervals are
lengthened appropriately.
The first case illustrates the difficulties in managing
postoperative pain in patients with renal disease,
including patients who appear to have relatively mild
renal dysfunction when assessed by measurement of
serum creatinine. We suspected opiate toxicity at an
early stage but discounted it because of an inadequate
response to naloxone, which had unwittingly been
administered subcutaneously. Subsequently, we gave
naloxone via an intravenous infusion. We continued
this for 48 hours, as the half life of naloxone is much
shorter than that of morphine-6-glucuronide in
patients with renal failure. Respiratory depression has
been reported up to 12 hours after stopping the
naloxone infusion.4 Indeed, we have previously
observed life threatening opiate toxicity occurring
more than 12 hours after withdrawal of patient
controlled analgesia, when the protocol driven
monitoring of respiratory function had already been
discontinued. Finally, reversal of opiate toxicity
coincided with the resolution of acute renal failure, a
phenomenon previously described and probably
reflecting morphine’s haemodynamic effects.5
The second case emphasises that life threatening
side effects may also result from conventional doses of
less potent opioid drugs in patients with chronic
kidney disease. Similar effects have been encountered
with other weak opiates, including over the counter
preparations.6 7 Although we do not have definitive evi-
dence of opiate toxicity, because naloxone was not
given in this case, strong circumstantial evidence exists.
Firstly, the patient’s pupils were small despite giving
her atropine and adrenaline. Secondly, the patient had
recovered sufficiently from her cardiorespiratory arrest
to obey commands and yet made no respiratory effort.
Finally, there was a rapid improvement in respiratory
function after removal of opiate metabolites during
haemodialysis.
In conclusion, in patients with renal dysfunction,
opiates and their active metabolites may accumulate,
resulting in potentially life threatening toxicity. Use of
non-opioid drugs should be considered and when opi-
ates are necessary, those that tend not to accumulate in
renal disease, such as buprenorphine or alfentanil, may
be preferred for mild and more severe pain,
respectively. Both medical staff and patients must be
aware that patients with renal dysfunction have an
increased risk of toxicity due to opiates, including over
the counter preparations.
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A memorable patient
Students forever
An elderly woman was admitted under my care after an extensive
myocardial infarction. After I had explained her prognosis to the
waiting relatives, they asked me to speak to another family
member, a retired professor of medicine. When I telephoned him,
I was surprised to discover that he was my professor from 20
years ago when I was at medical college. He cautioned me about
the risk of conduction block as well as heart failure.
On the third day after the patient’s admission, he called me to
suggest referring the patient to him for further management. This
pricked my ego as a senior physician, and I declined—the patient
was recovering well, and I said I was able to handle any
emergencies. Barely two hours later, she collapsed as she sat up in
bed. I found that she had intermittent heart block and had
collapsed because of a Stokes-Adams attack. I advised transfer to
a specialist cardiac centre for emergency pacemaker
implantation. Once again the relatives contacted my old
professor; oddly, he asked me not to transfer the patient, as the
risk was unacceptable. I did not argue, the patient made a smooth
recovery, and her family applauded me for my bold decision to
treat her.
We tend to become more confident with age and experience.
We may even feel more knowledgeable than our teachers and
deride their unfamiliarity with state of the art tools and modern
treatments. But incidents like this teach us that, in their eyes, we
remain students forever.
Sadananda B Naik physician, Alvas Health Centre,Moodabidri,
Karnataka, India (sadananda@consultant.com)
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